277 related articles for article (PubMed ID: 37188907)
1. Role of sarcopenia on survival and treatment-related toxicity in head and neck cancer: a narrative review of current evidence and future perspectives.
Erul E; Guven DC; Onur MR; Yazici G; Aksoy S
Eur Arch Otorhinolaryngol; 2023 Aug; 280(8):3541-3556. PubMed ID: 37188907
[TBL] [Abstract][Full Text] [Related]
2. Sarcopenia and its impact in head and neck cancer treatment.
de Bree R; van Beers MA; Schaeffers AWMA
Curr Opin Otolaryngol Head Neck Surg; 2022 Apr; 30(2):87-93. PubMed ID: 35255045
[TBL] [Abstract][Full Text] [Related]
3. Skeletal muscle mass at C3 may not be a strong predictor for skeletal muscle mass at L3 in sarcopenic patients with head and neck cancer.
Yoon JK; Jang JY; An YS; Lee SJ
PLoS One; 2021; 16(7):e0254844. PubMed ID: 34280248
[TBL] [Abstract][Full Text] [Related]
4. Nutritional status and skeletal muscle status in patients with head and neck cancer: Impact on outcomes.
Findlay M; White K; Brown C; Bauer JD
J Cachexia Sarcopenia Muscle; 2021 Dec; 12(6):2187-2198. PubMed ID: 34676673
[TBL] [Abstract][Full Text] [Related]
5. Impact of sarcopenia on acute radiation-induced toxicity in head and neck cancer patients.
Karavolia E; van Rijn-Dekker MI; Van den Bosch L; van den Hoek JGM; Oldehinkel E; Meijer TWH; Halmos GB; Witjes MJH; Oosting SF; van der Hoorn A; Langendijk JA; Steenbakkers RJHM
Radiother Oncol; 2022 May; 170():122-128. PubMed ID: 35304862
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of using head and neck CT imaging to assess skeletal muscle mass in head and neck cancer patients.
Swartz JE; Pothen AJ; Wegner I; Smid EJ; Swart KM; de Bree R; Leenen LP; Grolman W
Oral Oncol; 2016 Nov; 62():28-33. PubMed ID: 27865369
[TBL] [Abstract][Full Text] [Related]
7. The Association Between Computed Tomography-Defined Sarcopenia and Outcomes in Adult Patients Undergoing Radiotherapy of Curative Intent for Head and Neck Cancer: A Systematic Review.
Findlay M; White K; Lai M; Luo D; Bauer JD
J Acad Nutr Diet; 2020 Aug; 120(8):1330-1347.e8. PubMed ID: 32711854
[TBL] [Abstract][Full Text] [Related]
8. Image-based analysis of skeletal muscle mass predicts cisplatin dose-limiting toxicity in patients with locally advanced head and neck cancer.
Chargi N; Bashiri F; Wendrich AW; Smid EJ; de Jong PA; Huitema ADR; Devriese LA; de Bree R
Eur Arch Otorhinolaryngol; 2022 Jul; 279(7):3685-3694. PubMed ID: 35038029
[TBL] [Abstract][Full Text] [Related]
9. Measurement of Sarcopenia in Head and Neck Cancer Patients and Its Association With Frailty.
de Bree R; Meerkerk CDA; Halmos GB; Mäkitie AA; Homma A; Rodrigo JP; López F; Takes RP; Vermorken JB; Ferlito A
Front Oncol; 2022; 12():884988. PubMed ID: 35651790
[TBL] [Abstract][Full Text] [Related]
10. Sarcopenia in head and neck cancer: A scoping review.
Jovanovic N; Chinnery T; Mattonen SA; Palma DA; Doyle PC; Theurer JA
PLoS One; 2022; 17(11):e0278135. PubMed ID: 36441690
[TBL] [Abstract][Full Text] [Related]
11. Sarcopenia and myosteatosis in patients undergoing curative radiotherapy for head and neck cancer: Impact on survival, treatment completion, hospital admission and cost.
Findlay M; Brown C; De Abreu Lourenço R; White K; Bauer J
J Hum Nutr Diet; 2020 Dec; 33(6):811-821. PubMed ID: 32609428
[TBL] [Abstract][Full Text] [Related]
12. Nutrition impact symptoms and associated outcomes in post-chemoradiotherapy head and neck cancer survivors: a systematic review.
Crowder SL; Douglas KG; Yanina Pepino M; Sarma KP; Arthur AE
J Cancer Surviv; 2018 Aug; 12(4):479-494. PubMed ID: 29556926
[TBL] [Abstract][Full Text] [Related]
13. The impact of sarcopenia on tolerance of radiation and outcome in patients with head and neck cancer receiving chemoradiation.
Ganju RG; Morse R; Hoover A; TenNapel M; Lominska CE
Radiother Oncol; 2019 Aug; 137():117-124. PubMed ID: 31085391
[TBL] [Abstract][Full Text] [Related]
14. Low skeletal muscle mass is a predictive factor for chemotherapy dose-limiting toxicity in patients with locally advanced head and neck cancer.
Wendrich AW; Swartz JE; Bril SI; Wegner I; de Graeff A; Smid EJ; de Bree R; Pothen AJ
Oral Oncol; 2017 Aug; 71():26-33. PubMed ID: 28688687
[TBL] [Abstract][Full Text] [Related]
15. The impact of sarcopenia on survival and treatment tolerance in patients with head and neck cancer treated with chemoradiotherapy.
Bentahila R; Giraud P; Decazes P; Kreps S; Nay P; Chatain A; Fabiano E; Durdux C
Cancer Med; 2023 Feb; 12(4):4170-4183. PubMed ID: 36263581
[TBL] [Abstract][Full Text] [Related]
16. Skeletal muscle mass and sarcopenia can be determined with 1.5-T and 3-T neck MRI scans, in the event that no neck CT scan is performed.
Zwart AT; Becker JN; Lamers MJ; Dierckx RAJO; de Bock GH; Halmos GB; van der Hoorn A
Eur Radiol; 2021 Jun; 31(6):4053-4062. PubMed ID: 33219847
[TBL] [Abstract][Full Text] [Related]
17. Sarcopenia in male patients with head and neck cancer receiving chemoradiotherapy: a longitudinal pilot study.
Chauhan NS; Samuel SR; Meenar N; Saxena PP; Keogh JWL
PeerJ; 2020; 8():e8617. PubMed ID: 32149024
[TBL] [Abstract][Full Text] [Related]
18. CT-measured skeletal muscle mass used to assess frailty in patients with head and neck cancer.
Zwart AT; van der Hoorn A; van Ooijen PMA; Steenbakkers RJHM; de Bock GH; Halmos GB
J Cachexia Sarcopenia Muscle; 2019 Oct; 10(5):1060-1069. PubMed ID: 31134765
[TBL] [Abstract][Full Text] [Related]
19. Sarcopenia with inflammation as a predictor of survival in patients with head and neck cancer.
Yamahara K; Mizukoshi A; Lee K; Ikegami S
Auris Nasus Larynx; 2021 Oct; 48(5):1013-1022. PubMed ID: 33883097
[TBL] [Abstract][Full Text] [Related]
20. Association of low skeletal muscle mass and systemic inflammation with surgical complications and survival after microvascular flap reconstruction in patients with head and neck cancer.
Chargi N; Breik O; Forouzanfar T; Martin T; Praveen P; Idle M; Parmar S; de Bree R
Head Neck; 2022 Oct; 44(10):2077-2094. PubMed ID: 35652420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
